Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;28(1):3-9.
doi: 10.1016/j.smim.2015.12.001. Epub 2016 Jan 12.

Chimeric antigen receptor-redirected T cells return to the bench

Claudia Geldres  1 , Barbara Savoldo  2 , Gianpietro Dotti  3
Affiliations
Review

Chimeric antigen receptor-redirected T cells return to the bench

Claudia Geldres et al. Semin Immunol. 2016 Feb.

Abstract

While the clinical progress of chimeric antigen receptor T cell (CAR-T) immunotherapy has garnered attention to the field, our understanding of the biology of these chimeric molecules is still emerging. Our aim within this review is to bring to light the mechanistic understanding of these multi-modular receptors and how these individual components confer particular properties to CAR-Ts. In addition, we will discuss extrinsic factors that can be manipulated to influence CAR-T performance such as choice of cellular population, culturing conditions and additional modifications that enhance their activity particularly in solid tumors. Finally, we will also consider the emerging toxicity associated with CAR-Ts. By breaking apart the CAR and examining the role of each piece, we can build a better functioning cellular vehicle for optimized treatment of cancer patients.

Keywords: Adoptive immunotherapy; Chimeric antigen receptor.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Construction of CAR molecules
Schematic representation and functional characterization of CAR molecules
See this image and copyright information in PMC

References

    1. Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J. 2014 Mar;20(2):112–8. - PMC - PubMed
    1. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013 May;10(5):267–76. - PMC - PubMed
    1. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015 Jun 25;125(26):4017–23. - PMC - PubMed
    1. Sadelain M, Brentjens R, Riviere I, Park J. CD19 CAR Therapy for Acute Lymphoblastic Leukemia. Am Soc Clin Oncol Educ Book. 2015;35:e360–e363. - PubMed
    1. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov;14(11):1264–70. - PMC - PubMed

MeSH terms

Substances